177.63
0.83%
-0.445
前日終値:
$178.08
開ける:
$180.5
24時間の取引高:
144.47K
Relative Volume:
0.22
時価総額:
$9.72B
収益:
$4.06B
当期純損益:
$413.08M
株価収益率:
22.18
EPS:
8.01
ネットキャッシュフロー:
$560.48M
1週間 パフォーマンス:
-6.02%
1か月 パフォーマンス:
-7.28%
6か月 パフォーマンス:
-18.33%
1年 パフォーマンス:
-16.50%
Charles River Laboratories International Inc Stock (CRL) Company Profile
名前
Charles River Laboratories International Inc
セクター
電話
781-222-6000
住所
251 BALLARDVALE ST, WILMINGTON, MA
CRL を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
177.51 | 9.72B | 4.06B | 413.08M | 560.48M | 8.01 |
TMO
Thermo Fisher Scientific Inc
|
560.87 | 213.05B | 42.37B | 6.14B | 7.78B | 15.95 |
DHR
Danaher Corp
|
240.78 | 171.63B | 23.74B | 3.89B | 4.98B | 5.24 |
A
Agilent Technologies Inc
|
145.25 | 40.96B | 6.51B | 1.29B | 1.37B | 4.42 |
IQV
Iqvia Holdings Inc
|
198.91 | 35.93B | 15.32B | 1.41B | 1.96B | 7.62 |
IDXX
Idexx Laboratories Inc
|
429.09 | 34.28B | 3.84B | 866.24M | 792.60M | 10.37 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-18 | ダウングレード | CLSA | Hold → Underperform |
2024-11-07 | アップグレード | CLSA | Underperform → Hold |
2024-10-23 | 開始されました | CLSA | Underperform |
2024-10-14 | 開始されました | Redburn Atlantic | Sell |
2024-10-07 | ダウングレード | Evercore ISI | Outperform → In-line |
2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
2024-10-01 | ダウングレード | Citigroup | Neutral → Sell |
2024-08-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-08-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2024-06-28 | ダウングレード | Argus | Buy → Hold |
2024-06-07 | 開始されました | Mizuho | Neutral |
2024-06-06 | 開始されました | Goldman | Buy |
2024-02-15 | ダウングレード | Guggenheim | Buy → Neutral |
2023-09-13 | 開始されました | TD Cowen | Market Perform |
2023-07-10 | ダウングレード | Citigroup | Buy → Neutral |
2023-02-23 | アップグレード | Guggenheim | Neutral → Buy |
2023-01-12 | ダウングレード | Jefferies | Buy → Hold |
2022-09-30 | アップグレード | Jefferies | Hold → Buy |
2022-08-25 | 開始されました | Credit Suisse | Outperform |
2022-08-04 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | 開始されました | Guggenheim | Neutral |
2022-04-25 | ダウングレード | Jefferies | Buy → Hold |
2022-04-07 | 開始されました | Stephens | Overweight |
2022-02-17 | 繰り返されました | BofA Securities | Buy |
2022-02-17 | アップグレード | Citigroup | Neutral → Buy |
2022-02-17 | 繰り返されました | Deutsche Bank | Buy |
2022-02-17 | 繰り返されました | Morgan Stanley | Overweight |
2022-02-17 | 繰り返されました | UBS | Buy |
2021-08-05 | 再開されました | Credit Suisse | Neutral |
2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
2020-09-10 | アップグレード | Jefferies | Hold → Buy |
2020-07-01 | アップグレード | BofA Securities | Neutral → Buy |
2020-05-13 | アップグレード | UBS | Neutral → Buy |
2020-04-21 | ダウングレード | Jefferies | Buy → Hold |
2020-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | 開始されました | Deutsche Bank | Buy |
2020-02-18 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | アップグレード | Goldman | Neutral → Buy |
2020-01-08 | 開始されました | Wells Fargo | Overweight |
2020-01-07 | 開始されました | Citigroup | Buy |
2019-10-18 | ダウングレード | BofA/Merrill | Buy → Neutral |
2019-06-10 | 開始されました | SVB Leerink | Outperform |
2019-04-30 | 再開されました | Evercore ISI | Outperform |
2018-12-14 | 開始されました | Deutsche Bank | Buy |
2018-10-09 | 開始されました | UBS | Neutral |
2018-08-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
2018-07-17 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | アップグレード | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | アップグレード | SunTrust | Hold → Buy |
すべてを表示
Charles River Laboratories International Inc (CRL) 最新ニュース
Charles River Labs stock target cut, hold rating on expected decline - Investing.com
Charles River Laboratories International (NYSE:CRL) Reaches New 1-Year LowHere's Why - MarketBeat
Citi flags revenue and margin headwinds for Charles River Labs shares By Investing.com - Investing.com South Africa
Charles River Seeks Strategic Acquisitions - Marketscreener.com
Charles River Laboratories International's (CRL) "Outperform" Rating Reiterated at William Blair - MarketBeat
BofA keeps Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com Canada
TD Cowen cautious on Charles River Labs stock as 2025 guide signals further declines - Investing.com India
JPMorgan maintains Charles River Labs stock at Neutral on challenges - Investing.com India
Citi flags revenue and margin headwinds for Charles River Labs shares - Investing.com India
Charles River Laboratories International (NYSE:CRL) Shares Gap DownWhat's Next? - MarketBeat
Charles River Labs stock hits 52-week low at $176.34 By Investing.com - Investing.com Canada
JPMorgan maintains Charles River Labs stock at Neutral on challenges By Investing.com - Investing.com Nigeria
Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies - GlobeNewswire Inc.
Charles River Laboratories (CRL) Provides Preliminary 2025 Finan - GuruFocus.com
Charles River falls after projecting 2025 revenue drop - MSN
Charles River Labs stock hits 52-week low at $176.34 - Investing.com India
Charles River stock falls on 2025 revenue drop (CRL:NYSE) - Seeking Alpha
Charles River Labs Discusses 2025 Financial Outlook - TipRanks
Charles River Laboratories stock falls on weak 2025 revenue outlook By Investing.com - Investing.com UK
Bioanalytical Testing Services Market Size, Embracing Growth - openPR
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
Reinhart Partners LLC. Sells 11,822 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference - sharewise
Charles River Labs to Present Strategic Overview at J.P. Morgan Healthcare Conference - StockTitan
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
First Hawaiian Bank Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch
What Charles River Laboratories International, Inc.'s (NYSE:CRL) P/E Is Not Telling You - Simply Wall St
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Deciphex Secures $32.3M Series C to Transform AI-Powered Pathology Diagnosis - StockTitan
Preclinical Medical Device Testing Services Market Outlook, - GlobeNewswire
Preclinical Medical Device Testing Services Market Outlook, 2025-2035Dominated by Charles River Laboratories Int'l, Eurofins Scientific, SGS, WuXi AppTec, and Pace Analytical Services - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Should You Retain Charles River Stock in Your Portfolio Now? - MSN
CHARLES RIVER LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Ag - AccessWire
Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector? - MSN
Charles River Laboratories Stock: Is CRL Underperforming The Healthcare Sector? - Barchart
Zacks Research Issues Negative Forecast for CRL Earnings - MarketBeat
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Declining Stock and Solid Fundamentals: Is The Market Wrong About Charles River Laboratories International, Inc. (NYSE:CRL)? - Simply Wall St
RNA Therapy Clinical Trials Market Top Companies StudyIQVIA; - openPR
Charles River Laboratories International Inc. stock rises Tuesday, still underperforms market - MarketWatch
Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Interesting CRL Put And Call Options For August 2025 - Nasdaq
Earnings are growing at Charles River Laboratories International (NYSE:CRL) but shareholders still don't like its prospects - Yahoo Finance
Charles River Laboratories International, Inc. (NYSE:CRL) Receives $214.00 Average Price Target from Brokerages - MarketBeat
Bioanalytical Services Market Key Players AnalysisPPD, Inc., - openPR
Sanctuary Advisors LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International Inc (CRL) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):